Dr Reddy’s Laboratories (DRL) on Sunday said the company has launched five generic drugs in the US market during the last month, which together have a potential market value of over $3.78 billion.

The company launched generics or process-changed cheap versions of UCB's Keppra, Prilosec DR (Astra Zeneca), Prilosec CD (GlaxoSmithKline), Abbott’s Depakote and GlaxoSmithKline’s Lamictal, following approval from the US FDA. However, the company lacks exclusive rights to sell any of these drugs and therefore, will have to compete with other generic drug makers having approvals for these products. When a drug goes off-patent in the US, prices often falls over 90 per cent due to generic competition.

Dr Reddy's had posted over 151 per cent jump in its net profits for the third quarter, mainly driven by the exclusive six month launch of an authorised generic version of GlaxoSmithKline’s Imitrex (sumatriptan succinate), in late November 2008.

Dr Reddy's had received approvals for generics of epilepsy drug Keppra (Levetiracetam) tablets in 250mg, 500mg, 750mg and 1000mg category. According to IMS sales figures, it had annual sales of $1.1 billion for the 12 month sales ending September 2008. In October 2007, Dr Reddy's had reached an out of court settlement on the patent infringement case with UCB on Keppra, along with Mylan.

Prilosec delayed release (DR) tablets (omeprazol) of AstraZeneca had an annual sales of $168 million for the 12 month period. The drug is indicated in the treatment of stomach ulcers and acid reflux.

GlaxoSmithKline’s Prilosec CD tablets had recorded an annual sales of $87 million and Abbott’s Depakote Delayed Release capsules had an annual sales of $126 million. The approval for Dr Reddy's are for 5mg and 25mg versions of Prilosec and for 125 mg version of generic Depakote, which is indicated for the treatment of manic episodes associated with bipolar disorders.

Dr Reddy's got approval for 25mg, 100mg, 150mg and 200mg of lamotrigine tablets, the generic version of GlaxoSmithKline’s Lamictal tablets, a drug with annual sales of $2.3 billion. Lamictal is to treat seizures and bipolar disorder. The drug lost patent protection in July last year.

New Ipad Application :Business Standard's all new IPad App Click here to download for free Other Stories      - Wall Street opens higher on Greek deal - Oil cos seek compensation for losses on petrol - Centre for 6% road tax on cars, two-wheelers - RBI raises bank rate to 9.5% - Axis Bank reappoints Shikha Sharma as Managing Director

Read Business news in  Advertisements -  Now property search gets more exciting than ever before! -  High Growth Business Opportunities in Africa - Register to explore -  Save over Rs.3000 with IndianOil Citibank Card -  We live for our family. have you secured them? -  Are You Serious About Your Future? Click here to know more -  Financial Learning now made easier and more convenient. -  India's No. 1 Property Site. Click here to know more.. -  Get 5% cashback on telephone bills with Citi -  Exim Bank Conclave on India - Africa Project Partnership. Know more.. -  Be part of it The World's Largest Aircraft. -  Creating Wealth made simple the SIP way. Know more.. -  Only Developer to give a guarantee on time space & rate. -  Office 365 for professionals and small businesses. -  Buy Your Property with Our Triple Guarantee in India. -  Improve Patient Care & Experience. Click here to know more -  Win a Business Class Ticket to Europe..Know more.. -   Introduce a New Automotive Luxury Car.. know more -  Health is Wealth..... Insurance + Savings... Know More...